RCUS Q2 2024 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$39M+34.5% YoY

Gross Profit

$39M100.0% margin

Operating Income

-$106M-271.8% margin

Net Income

-$93M-238.5% margin

EPS (Diluted)

$-1.02

QoQ Revenue Growth

-73.1%

Cash Flow

Operating Cash Flow

-$94M

Free Cash Flow

-$94M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$551M

Stockholders' Equity

$635M

Cash & Equivalents

$156M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$39M	$29M	+34.5%
Gross Profit	$39M	$29M	+34.5%
Operating Income	-$106M	-$83M	-27.7%
Net Income	-$93M	-$75M	-24.0%

Revenue Segments

License and Development Services Revenue

$28M72%

Other Collaboration Revenue

$11M28%